SCHEMBL20861817

SCHEMBL20861817

Cc1ccc(F)c(NC(=O)Nc2cccc3ccccc23)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.76
MEN1 O00255 5/20 0.76
RAB9A P51151 5/20 0.66
NPC1 O15118 2/20 0.58
KDM4E B2RXH2 6/20 0.58
MAPT P10636 6/20 0.58
POLB P06746 2/20 0.56
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 2/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 2/20 0.52
GRIK1 P39086 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
GAA P10253 1/20 0.52
CYP2C19 P33261 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
PDGFRB P09619 2/20 0.52
KDR P35968 2/20 0.52
EPHX1 P07099 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6724021 0.87 KMT2A (0.78) KMT2AMEN1RAB9ANPC1KDM4E
Hydrochloric Acid SCHEMBL7203895 0.86 KMT2A (0.76) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL6568502 0.82 RAB9A (0.68) KMT2AMEN1RAB9AKDM4EMAPT
SCHEMBL17929424 0.81 PDGFRB (0.55) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL1276481 0.80 KDM4E (0.82) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL30393282 0.80 KDM4E (0.82) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL31328460 0.80 RAB9A (0.70) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL11052575 0.80 RAB9A (1.00) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL4345368 0.77 RAB9A (0.65) KMT2AMEN1RAB9ANPC1KDM4E
SCHEMBL6724026 0.76 SIGMAR1 (0.63) KMT2AMEN1RAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3050881-B1 NOVEL A-NAPHTHYLUREA DERIVATIVE AND MEDICAL APPLICATION OF THE SAME IN THE TREATMENT OF VISUAL LOSS AND CANCER DISEASES SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) 2019-04-03 EP disclosed